Previous 10 | Next 10 |
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , iTunes...
SOUTH SAN FRANCISCO, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will present at tw...
WATERTOWN, Mass., June 20, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced the appoi...
Cyclacel Pharmaceuticals (NASDAQ: CYCC ) initiated with Buy rating and $8 (1173% upside) price target at Roth Capital Partners. More news on: Cyclacel Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Inc., Fate Therapeutics, Inc., Healthcare stocks news, , Stocks on the move, Read more ...
Harpoon Therapeutics (NASDAQ: HARP ): Q1 GAAP EPS of -$0.92 misses by $0.50 . More news on: Harpoon Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Continued enrollment of Phase 1 trial for HPN424, Harpoon’s lead TriTAC product candidate in development for the treatment of prostate cancer Net proceeds of approximately $71 million from completion of initial public offering in February SOUTH SAN FRANCISCO, Calif., May 09, 201...
Novartis ( NVS ): The stock has been tumbling after the company announced interim data from the Phase 2 STR1VE trial of Zolgensma/AVXS-101 in spinal muscular atrophy ( SMA ) Type 1. While it's true that prolonged event-free survival and rapid increase in CHOP-INTEND scores were encouragi...
Harpoon Therapeutics (NASDAQ: HARP ) has dosed first patient with HPN536 in a Phase 1/2a clinical trial initially focused on ovarian cancer. More news on: Harpoon Therapeutics, Inc., Healthcare stocks news, Read more ...
HPN536 is the second TriTAC T cell engager to enter clinical development from the Harpoon pipeline Trial initiated at Sarah Cannon Research Institute in Nashville, Tenn. - a leading drug development organization SOUTH SAN FRANCISCO, Calif., April 18, 2019 (GLOBE NEWSWIRE) -- Harpoo...
The first quarter of 2019 was robust with activity for the biotechnology industry thanks to merger and acquisitions (M&A) in addition to initial public offerings (IPOs). Looking back to the end of last year, the biotech sector took a significant hit in terms of stock performance, ...
News, Short Squeeze, Breakout and More Instantly...
Harpoon Therapeutics Inc. Company Name:
HARP Stock Symbol:
NASDAQ Market:
Harpoon Therapeutics Inc. Website:
Community Bancorp Inc Vermont (CMTV) is expected to report for Q4 2023 CISO Global, Inc (CISO) is expected to report for Q4 2023 TCTM Kids IT Education Inc. (TCTM) is expected to report for quarter end 2023-12-31 Generation Income Properties Inc. (GIPR) is expected to report for quart...
2024-02-14 02:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-23 08:45:00 ET On Jan. 8, pharmaceutical giant Merck (NYSE: MRK) moved to acquire biotech Harpoon Therapeutics , (NASDAQ: HARP) for $680 million in cash. The point of the acquisition, which should close in the first half of this year, is to gain access to Harpoon's t...